ArticleThorax2012
Progress in cystic fibrosis and the CF Therapeutics Development Network.
Article in Thorax, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 70 citations in OpenAlex.
- Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.Annals of the American Thoracic Society · 2015Trial
- Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.Contemporary clinical trials · 2013Trial
- Novel use of a hash-based tokenization for sharing sickle cell disease data without sharing protected health information.Blood advances · 2026Article
- Statistical approaches for the integration of external controls in a cystic fibrosis clinical trial: a simulation and an application.American journal of epidemiology · 2024Article
- Rethinking heart failure clinical trials: the heart failure collaboratory.Frontiers in cardiovascular medicine · 2024Review
- Lessons Learned from a University-School District Partnership to Improve Autism Care in Public Schools.Journal of educational and psychological consultation : the official journal of the Association for Educational and Psychological Consultants · 2024Article
- Potential implicit bias in attribution of adverse events in randomized controlled trials in cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2023Article
- Establishing a Cystic Fibrosis Learning Network: Interventions to promote collaboration and data-driven improvement at scale.Learning health systems · 2023Article
- Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design.BMJ open respiratory research · 2022Article
- Lung-kidney interactions and their role in chronic kidney disease-associated pulmonary diseases.American journal of physiology. Lung cellular and molecular physiology · 2022Review
- Rates of adverse and serious adverse events in children with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021Article
- Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design.Annals of the American Thoracic Society · 2021Article
- Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis.Trends in molecular medicine · 2020Review
- Gene therapy randomised clinical trials in Europe - a review paper of methodology and design.Journal of market access & health policy · 2020Review
- Prognostication and Risk Factors for Cystic Fibrosis via Automated Machine Learning.Scientific reports · 2018Article
- Academic, Foundation, and Industry Collaboration in Finding New Therapies.The New England journal of medicine · 2017Review
- The Northwest Participant and Clinical Interactions Network: Increasing opportunities for patients to participate in research across the Northwestern United States.Journal of clinical and translational science · 2017Article
- Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study.The Lancet. Respiratory medicine · 2016Article
- Review
- Chest CT abnormalities and quality of life: relationship in adult cystic fibrosis.Annals of translational medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 1 country.
Funding
Abstract
Cystic fibrosis (CF), the most common life-shortening genetic disorder in Caucasians, affects approximately 70 000 individuals worldwide. In 1998, the Cystic Fibrosis Foundation (CFF) launched the CF Therapeutics Development Network (CF-TDN) as a central element of its Therapeutics Development Programme. Designed to accelerate the clinical evaluation of new therapies needed to fulfil the CFF mission to control and cure CF, the CF-TDN has conducted 75 clinical trials since its inception, and has contributed to studies as varied as initial safety and proof of concept trials to pivotal programmes required for regulatory approval. This review highlights recent and significant research efforts of the CF-TDN, including a summary of contributions to studies involving CF transmembrane conductance regulator (CFTR) modulators, airway surface liquid hydrators and mucus modifiers, anti-infectives, anti-inflammatories, and nutritional therapies. Efforts to advance CF biomarkers, necessary to accelerate the therapeutic goals of the network, are also summarised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.